Endothelin-converting enzyme inhibitors: current status and perspectives

J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S79-82. doi: 10.1097/00005344-200000002-00018.

Abstract

Recent research has led to the discovery of potent selective or mixed endothelin-converting enzyme (ECE), ECE/neutral endopeptidase24.11 (NEP) and ECE/NEP24.11/angiotensin-converting enzyme (ACE) inhibitors. There is also increasing evidence, that the functions of the endothelin (ET), renin-angiotensin and NEP systems for the regulation of the cardiovascular homeostasis are connected by a complex regulation network. It will be the challenging task of future research with the newly available selective and mixed ECE-1 inhibitors to show whether the combined inhibition of more than one cardiovascular system is superior to selective inhibition.

Publication types

  • Review

MeSH terms

  • Angiotensins / antagonists & inhibitors
  • Angiotensins / physiology
  • Animals
  • Aspartic Acid Endopeptidases / antagonists & inhibitors*
  • Aspartic Acid Endopeptidases / chemistry
  • Aspartic Acid Endopeptidases / physiology
  • Cardiovascular Physiological Phenomena
  • Cardiovascular System / physiopathology
  • Endothelin-Converting Enzymes
  • Humans
  • Metalloendopeptidases
  • Neprilysin / antagonists & inhibitors
  • Neprilysin / physiology
  • Renin / antagonists & inhibitors
  • Renin / physiology

Substances

  • Angiotensins
  • Aspartic Acid Endopeptidases
  • Renin
  • Metalloendopeptidases
  • Neprilysin
  • ECE1 protein, human
  • Endothelin-Converting Enzymes